Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gene editing
Research
Ex-bluebird execs hope to fly startup to delivery tech heights
A startup founded by genetic medicine luminaries and run by former executives from bluebird bio is officially emerging from stealth mode.
Helen Floersh
Apr 9, 2024 7:00am
Verve halts VERVE-101 enrollment, focuses on 2nd PCSK9 editor
Apr 2, 2024 7:00am
Intellia opts out of hemophilia gene editing work with Regeneron
Mar 22, 2024 11:21am
Metagenomi, Telomir offer double test case for preclinical IPOs
Feb 9, 2024 7:00am
Gene editing biotech Metagenomi plans modest $87M IPO
Feb 5, 2024 9:14am
Genevant secures $114M deal with Tome to develop liver therapy
Jan 16, 2024 10:11am